

MANAGEMENT OF CARDIOMYOPATHY

Essay

**Submitted for partial fulfillment of master degree
in General Intensive Care**

By

Hadeel Abdullah Mahmoud Ali Eid

M.B.,B.Ch.

Supervised By

Prof. Alaa Abd El Wahab korraa

**Professor of Anaesthesia and Intensive Care
Faculty of Medicine - Ain Shams University**

Supervised

Dr. Nevien Ahmad Hassan Kashef

**Assistant Prof. of Anaesthesia and Intensive Care
Faculty of Medicine - Ain Shams University**

Dr. Ghada Mohamed Samir

**Lecturer of Anaesthesia and Intensive Care
Faculty of Medicine - Ain Shams University**

Faculty of Medicine

Ain Shams University

2013

ACKNOWLEDGEMENT

*First and above all, thanks and gratitude to the **Merciful God** for helping me to complete this work.*

*I would like to express my deep thanks, gratitude and appreciation to **professor Dr. Alaa Abd El Wahab Korraa** for his kind supervision and continuous encouragement throughout the course of this work.*

*Many great thanks and appreciation are owed to **Dr.Nevien Ahmad Kashef** for her great help and support during the conduction of this work.*

*I am much grateful to **Dr. Ghada Mohamed Samir** for her experienced guidance and advice that made the completion of this work possible.*

Lastly, my great thanks to my family; my mother and my father for their endless love and support. And many thanks to my husband for his efforts and support to complete this work.

Contents

Contents

➤ List of abbreviations	i-v
➤ List of tables	vi
➤ List of figures	vii-x
➤ Introduction	1-3
➤ Aim of Work	4
➤ Pathophysiology of cardiomyopathy	5-32
➤ Diagnostic tools of cardiomyopathy	33-70
➤ New trends in management of cardiomyopathy	71-113
➤ Summary	114-115
➤ References	116-138
➤ Arabic summary	139-140

List of abbreviations

Abbreviations

ACE: Angiotensin-Converting Enzyme

AF: Atrial Fibrillation

AHA: American Heart Association

Angiotensin II

AMP: Adenosine Monophosphate

ARB: Angiotensin-II Receptor Blocker

ARVC/D: Arrhythmogenic Right Ventricular
Cardiomyopathy /Dysplasia

ARVC: Arrhythmogenic Right Ventricular Cardiomyopathy

ASA: Alcohol Septal Ablation

β 1ARs: β 1-Adrenoceptors

BNP: Brain Natriuretic Peptide

CAD: Coronary Artery Disease

List of abbreviations

CMR: Cardiovascular Magnetic Resonance

CPVT: Catecholaminergic Polymorphic Ventricular
Tachycardia

CRT: Cardiac Resynchronisation Therapy

cTnI: Cardiac Troponin I

cTnT: Cardiac Troponin T

DCM: Dilated Cardiomyopathy

ECG : Electrocardiogram

EMF: Endomyocardial Fibrosis

ESC: European Society of Cardiology

FDC: Familial Dilated Cardiomyopathy

HCM: Hypertrophic Cardiomyopathy

HES: Hypereosinophilic Syndrome

HF : Heart Failure

List of abbreviations

H-FABP : Heart type Fatty Acid Binding protein

HFE: The official gene symbol for High Iron Fe

HFrEF : Heart Failure with Reduced Ejection Fraction

HH : Hereditary hemochromatosis

HJV : Hemojuvelin

ICD : Implantable Cardioverter Defibrillator

IFN-g : Interferon gamma

IL-6: Interlukin 6

IV: Intravenous

kDa: Kilodalton

LAD: Left-Axis Deviation

LAE : Left Atrial Enlargement

LAMP-2: Lysosome-Associated Membrane Protein-2

LBBB: Left Bundle Branch Block

List of abbreviations

LGE: Late Gadolinium Enhancement

LIM protein : Protein composed of LIM domains{Lin-11, Isl-1, Mec -3}

LQTS: Long QT Syndrome

LV: Left Ventricle

LVEF: Left Ventricular Ejection Fraction

LVH : Left Ventricular Hypertrophy

LVNC: Left Ventricular Noncompaction

LVOT: Left Ventricular Outflow Tract

NE: Norepinephrine

NICMP : Nonischemic Cardiomyopathy

NYHA : New York Heart Association

PPCM: Peripartum Cardiomyopathy

PRKAG2: Activated Protein Kinase Gamma subunit 2

List of abbreviations

RBBB: Right Bundle Branch Block

RCM: Restrictive Cardiomyopathy

ROS: Reactive Oxygen Species

RV: Right Ventricle

Rx : Recipe (prescription)

SAM: Systolic Anterior Motion

SCD: Sudden Cardiac Death

SICM: Stress Induced Cardiomyopathy

SQTS: Short QT Syndrome

SUNDS: Sudden Unexplained Nocturnal Death Syndrome

SVT: Supraventricular Tachycardia

TFR2: Transferrin Receptor 2

TWI: T Wave Inversion

VAD: Ventricular Assist Device

Tables

List of tables

Table	Title	Page
1	Important secondary cardiomyopathies	7
2	Differential diagnosis in dilated cardiomyopathy	55

List of figures

Figure	Title	Page
1	Classification model for Primary cardiomyopathies	6
2	T wave inversion and ST depression in the inferolateral leads in a patient with hypertrophic cardiomyopathy	36
3	Abnormal Q waves (>3 mm in depth) in V5–V6, II and aVF in a patient with hypertrophic cardiomyopathy	36
4	Complete left bundle branch block in a patient with hypertrophic cardiomyopathy	37
5	Left atrial enlargement in a patient with hypertrophic cardiomyopathy	37
6	(A) Inverted T waves in a patient with ARVC	39

Figures

7	Delayed S wave upstroke and inverted T waves in a patient with arrhythmogenic right ventricular cardiomyopathy	40
8	Multiple premature ventricular complexes with a left bundle branch pattern and superior axis in a patient with ARVC	41
9	Resting sinus tachycardia, left atrial enlargement, T wave inversions in the lateral limb and precordial leads and deep S waves in a patient with idiopathic dilated cardiomyopathy	43
10	Inferior Q waves, poor R wave progression across the precordial leads with deep S waves and a single premature ventricular complex. High-degree AV block is also present in a young patient with dilated cardiomyopathy	44

Figures

11	ST segment depression in the inferolateral leads in a patient with isolated left ventricular non-compaction	45
12	Left atrial enlargement with a left bundle branch block. An isolated premature ventricular complex is also present in a patient with isolated left ventricular non-compaction	46
13	Typical asymmetrical left ventricular hypertrophy in patients with hypertrophic cardiomyopathy	54
14	Left ventricular non-compaction.	60
15	Diagnostic patterns of LGE. Distribution pattern and location of LGE contributes to the differential diagnosis between a NICMP and a typical ischaemic sub-endocardial enhancement (D	64
16	ARVC. Findings suggestive of ARVC include localized aneurysms in the RV outflow tract	69

Figures

17	A schematic summary of the pharmacologic therapy of HCM	76
----	---	----

Introduction

Progress of modern molecular biology and its introduction into clinical cardiovascular medicine has considerably changed the approach to cardiomyopathies and has led to new classification schemes. While cardiomyopathies were initially defined as disorders that were idiopathic, expert panels classify cardiomyopathies now into: primary, acquired and mixed. This results from the data published by the latest American Heart Association (AHA) (2006) and European Society of Cardiology (ESC) (2008) classifications segregating cardiomyopathies into familial/genetic and non-familial/non-genetic. Both recommendations define a cardiomyopathy as a myocardial disorder in which the heart muscle is structurally and functionally abnormal in the absence of coronary heart disease, hypertension, valvular heart disease and congenital heart disease sufficient to cause the observed myocardial abnormality. Cardiomyopathies are therefore grouped

into specific morphological and functional phenotypes and subclassified into familial and non-familial forms (*Parsai et al., 2012*).

The most common clinical presentation in patients with cardiomyopathy is heart failure. The evaluation for underlying causes of heart failure includes a thorough history and physical examination with baseline chemistries, including B-type natriuretic peptide (BNP) levels, echocardiography and electrocardiography (ECG). Echocardiography is key diagnostic modality for patients with suspected cardiomyopathy. The most important advance has been the use of cardiac MRI. Two aspects were prominent: the ability of cardiomagnetic resonance (CMR) to detect myocardial segments ‘invisible’ to echocardiography (e.g., posterior septum and apex) and probably and more importantly, the ability to image myocardial scar using gadolinium enhancement (*Bruder et al., 2010*).